Previous 10 | Next 10 |
home / stock / trypf / trypf news
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida Canada NewsWire Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its appointment of David L. Tousley, CPA, MBA, as a new independent director. Tousley replaces William Garner, M.D....
TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT Canada NewsWire Recognized industry leader brings deep finance and operational experience to Tryp board SAN DIEGO , Feb. 22, 2022 /CNW/ - Tryp Therapeutic...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has amended the terms of its non-brokered private placement previously announced on Feb. 4, 2022, and increased the maximum offerin...
Tryp Therapeutics (OTCQB:TRYPF) has upsized its previously announced private offering of common shares. Each share is being offered at $0.20 to raise aggregate gross proceeds of up to $6M. The company also secured a lead order from its co-Founder William Garner for $4M (20M common shares). Pu...
TRYP THERAPEUTICS INC. ANNOUNCES UPSIZING OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT Canada NewsWire REVISED DEAL INCLUDES INCREASE IN PREMIUM SHARE PRICE TO $0.20 PER SHARE WITHOUT WARRANTS PRIVATE PLACEMENT GROSS PROCEEDS OF UP TO $6 MILLION WITH $4 ...
(TheNewswire) SAN DIEGO – TheNewswire - February 4, 2022 – Tryp Therapeutics (CSE:TRYP) (CNSX:TRYP.CN) (OTC:TRYPF) (" Tryp ” or the “ Company "), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has reported its interim financial results for its first quarter 2022, the three-month period ended Nov. 30, 2021. Highlights ...
Tryp Therapeutics Announces Q1 2022 Financial Results Canada NewsWire SAN DIEGO , Jan. 28, 2022 /CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for dise...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase . The event...
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc Com Company Name:
TRYPF Stock Symbol:
OTCMKTS Market:
Tryp Therapeutics Inc Com Website:
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) (" Tryp " or the " Company ") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the " Financial Statements "), along with the corresponding Manage...
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...